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The use of glycated albumin in the management of diabetes mellitus. 
Glycated albumin (GA) is considered useful for assessing the degree of protein glycation directly dependent 
on glucose exposure.  The conventional biomarkers employed for screening and monitoring diabetes mellitus 
(DM) include fasting glucose, postprandial glucose and glycated hemoglobin (HbA1c). Although they 
provide useful information, in some clinical conditions they are inadequate. GA is an interesting biomarker 
for diabetes mellitus: 1) as it is an intermediate-term marker of the glycemic status, it gives more information 
than the short-term (glycemia) and long-term (HbA1c) biomarkers currently employed in clinical practice; 2) 
in specific clinical conditions (altered erythrocyte lifespan, pregnancy and end-stage renal disease) it should 
be preferred to HbA1c; 3) it is probably also useful for diabetes mellitus screening and risk stratification of 
diabetes-related complications.  HbA1c may be affected by any condition affecting erythrocyte lifespan 
(hemolytic anemia, hemorrhage, folate and vitamin B12 deficiency anemia, aplastic anemia, nephropathy) 
and hemoglobin metabolism (variant hemoglobin, thalassemia). Unlike HbA1c, GA is not influenced by 
their lifespan and is also independent of iron deficiency. In pregnancy HbA1c suffers some limits as an 
indicator of glycemic control since it raises from the second to the third trimester probably due to iron 
deficiency. Unlike HbA1c, GA is not affected by iron deficiency and, as an intermediate-term glycemic 
marker  (albumin turnover is shorter than erythrocyte lifespan - 20 vs. 120 days ), it enables pregnant women 
with DM to maintain a stricter glycemic control, important to lower the risk of fetal and maternal 
complications. GA is also a useful biomarker for monitoring diabetes mellitus in newborns due to the high 
levels of fetal hemoglobin. Patients with diabetes and end-stage renal diseases under dialysis also cannot be 
efficiently managed with HbA1c, because of the reduced persistence of red blood cells due to mechanical 
disruption, lower hemoglobin and erythropoietin concentration. GA may be a better indicator of their 
glycemic status. GA may be a useful diagnostic tool for diabetes screening in the general population and in 
individuals with a pre-diabetic condition. GA also rises sooner than HbA1c when glycemic status worsens, 
probably due to albumin biochemistry and its half-life . This means that GA is more useful as an indicator of 
glycemic status in all those conditions requiring short-term control of changes in glycemia, such as after the 
start or modifications of diabetes treatments.  GA may be also directly implicated in the development of 
different complications related to diabetes, playing a role as a pathogenic molecule. However, in some 
specific disorders GA levels are either lower or higher than the mean plasma glucose concentration, mainly 
because of changes in the albumin metabolism. 
In conclusion, the introduction of this biomarker in clinical practice could help clinicians in the diagnosis and 
monitoring of diabetes mellitus and in planning measures to prevent long-term diabetes complications.  
